蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 2390|回复: 1
收起左侧

[法律法规] FDA- Warning letter

[复制链接]
药徒
发表于 2018-8-31 13:47:46 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
Warning letter due to lacking cleaning validation, stability testing and content determinationIf different API syntheses are performed in a shared system, it is advisable in case of an FDA inspection to furnish explicit evidence that there is no chance of cross contamination due to the cleaning procedures established. Otherwise, this could lead to a warning letter. When FDA inspectors examined the facility of Chinese API manufacturer Sichuan Friendly Pharmaceutical, they did not only find severe defects regarding the validation of cleaning procedures for the non-dedicated production equipment. The stability testing of active substance batches did not comply with cGMP standards, either. Moreover, the determination of active substance content performed lead to completely false, out of specification (OOS) results. The warning letter published afterwards contained the following details:
Cleaning/Cleaning validation
There were no cleaning validation studies demonstrating that cross contamination could be eliminated beyond doubt. While cleaning runs had been carried out, only parts of the equipment had been cleaned, not the whole production system. They also neglected taking the possible carryover of class 2 and 3 solvents used in various syntheses into consideration. The company further failed to conduct residual solvent testing for intermediates and final products and thereby proving that the relevant limits - especially for potentially toxic class 2 solvents (e.g. chloroform, cyclohexane, methanol, etc.; see guideline ICH Q3C) - were not exceeded. In the company's response, the FDA criticised that there was no risk assessment for all API batches distributed into the USA regarding contamination with residual solvents.
Stability testing
Stability studies using stability-indicating measures in accordance with USP had not been conducted. The testing of retain samples followed the provisions of another pharmacopoeia. For products entering the US market however, the mandatory standards are those of the USP, according to which expiration dates and retesting periods must be determined. The company has therefore been prompted to submit a complete USP compliant stability program including all retain samples of active substance batches distributed to the USA.
Content determination
The Excel spreadsheet used by quality control to release finished product (as well as for the not USP compliant stability tests) had no password protection and no protection for the formulas to calculate release assay results. At closer inspection, the inspector also found the formula to be incorrect. Thereby, many certificates of analysis contained false values. Due to these OOS results of the API content, the batches should not have been released. The QC manager had already admitted to the mistake in the calculation formula during the inspection. The company's response did not address the insufficient procedures for reviewing data and analyses results; furthermore, there had been no information on how data integrity is to be ensured in the future.
Following the FDA warning letter to Sichuan Friendly Pharmaceutical the authority placed the company on Import Alert
回复

使用道具 举报

药士
发表于 2018-8-31 18:04:38 | 显示全部楼层
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2024-11-28 15:42

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表